Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

From the Department of Cardiology and Angiology I, University Heart Center Freiburg, Germany (D.W.) Faculty of Medicine, University of Freiburg, Germany (D.W.) K. Ley has received research funding for ...

Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics ...

In October 15 Genes & Development, Naomi Mukae and colleagues at Osaka University Medical School, Osaka, Japan, show that chromosomal DNA that escapes apoptotic degradation can induce activation of ...

Macrophage phagocytosis has been implicated in regulating anti-tumour immunity. Trained innate immunity (TII), induced via modulation of mature myeloid cells or their bone marrow progenitors, mediates ...